Many clinical studies have shown that HuR protein levels correlate with a malignant phenotype and/or patients’ prognosis in various cancer types (oral, esophageal, gastric, colorectal, gallbladder, renal, urothelial, pancreatic, lung, breast, cervical, and ovarian cancer). This evidence concerns the gene ELAVL1 and cancer.